The objective of this study is to design, develop, and synthesize novel random triblock (RTB) copolymers for sustained delivery of macromolecules. RTB copolymers have not been utilized for the delivery of macromolecules for ocular diseases. RTB copolymers comprising of polyethylene glycol, glycolide, and ɛ-caprolactone blocks were synthesized and assessed for their molecular weights and purity using 1H-NMR spectroscopy, gel permeation chromatography, FTIR (functionality), and XRD (crystallinity). No toxicity was observed when ocular cell lines were treated with RTB copolymers. These materials were applied for encapsulation of peptides and proteins (catalase, IgG, BSA, IgG Fab fragment, lysozyme, insulin, and octreotide) in nanoparticles. Particle size ranged from 202.41 ± 2.45 to 300.1 ± 3.11 nm depending on the molecular size and geometry of proteins/peptides. Polydispersity indices were between 0.26 ± 0.02 and 0.46 ± 0.07 respectively. Percentage entrapment efficiency and drug loading ranged from 83.44 ± 2.24 to 45.35 ± 5.53 and 21.56 ± 0.46 to 13.08 ± 1.35 respectively depending on molecular weights of peptides or proteins. A sustained in vitro release of macromolecule was observed over 3-month period. These results suggest that RTB copolymers may be suitable for sustained delivery systems for various macromolecules for different diseases including ocular diseases.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27(4):331–71.
Krock BL, Skuli N, Simon MC. Hypoxia-induced angiogenesis: good and evil. Genes Cancer. 2011;2(12):1117–33.
Vadlapatla RK, Vadlapudi AD, Mitra AK. Hypoxia-inducible factor-1 (HIF-1): a potential target for intervention in ocular neovascular diseases. Curr Drug Targets. 2013;14(8):919–35.
Qazi Y, Maddula S, Ambati BK. Mediators of ocular angiogenesis. J Genet. 2009;88(4):495–515.
Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012;87(1):77–88.
Relhan N, Flynn HW Jr. The Early Treatment Diabetic Retinopathy Study historical review and relevance to today’s management of diabetic macular edema. Curr Opin Ophthalmol. 2017;28:205–12.
Boyer DS, Hopkins JJ, Sorof J, Ehrlich JS. Anti-vascular endothelial growth factor therapy for diabetic macular edema. Ther Adv Endocrinol Metab. 2013;4(6):151–69.
Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013;27(7):787–94.
Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348–60.
Joseph M, Trinh HM, Cholkar K, Pal D, Mitra AK. Recent perspectives on the delivery of biologics to back of the eye. Expert Opin Drug Deliv. 2017;14(5)631–45.
Moisseiev E, Waisbourd M, Ben-Artsi E, Levinger E, Barak A, Daniels T, et al. Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes. Graefes Arch Clin Exp Ophthalmol. 2014;252(2):331–7.
Xu L, Lu T, Tuomi L, Jumbe N, Lu J, Eppler S, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci. 2013;54(3):1616–24.
Shikari H, Silva PS, Sun JK. Complications of intravitreal injections in patients with diabetes. Semin Ophthalmol. 2014;29(5–6):276–89.
Solaro R, Chiellini F, Battisti A. Targeted delivery of protein drugs by nanocarriers. Materials. 2010;3(3):1928–80.
Jiang Z, Hao J, You Y, Gu Q, Cao W, Deng X. Biodegradable thermogelling hydrogel of P(CL-GL)-PEG-P(CL-GL) triblock copolymer: degradation and drug release behavior. J Pharm Sci. 2009;98(8):2603–10.
Jiang Z, You Y, Deng X, Hao J. Injectable hydrogels of poly(ɛ-caprolactone-co-glycolide)–poly(ethylene glycol)–poly(ɛ-caprolactone-co-glycolide) triblock copolymer aqueous solutions. Polymer. 2007;48(16):4786–92.
Patel SP, Vaishya R, Mishra GP, Tamboli V, Pal D, Mitra AK. Tailor-made pentablock copolymer based formulation for sustained ocular delivery of protein therapeutics. J Drug Deliv 2014;2014:401747, 1, 15.
Patel SP, Vaishya R, Yang X, Pal D, Mitra AK. Novel thermosensitive pentablock copolymers for sustained delivery of proteins in the treatment of posterior segment diseases. Protein Pept Lett. 2014;21(11):1185–200.
Agrahari V, Agrahari V, Hung WT, Christenson LK, Mitra AK. Composite nanoformulation therapeutics for long-term ocular delivery of macromolecules. Mol Pharm. 2016;13(9):2912–22.
Patel SP, Vaishya R, Patel A, Agrahari V, Pal D, Mitra AK. Optimization of novel pentablock copolymer based composite formulation for sustained delivery of peptide/protein in the treatment of ocular diseases. J Microencapsul. 2016;33(2):103–13.
Patel A, Gaudana R, Mitra AK. A novel approach for antibody nanocarriers development through hydrophobic ion-pairing complexation. J Microencapsul. 2014;31(6):542–50.
Panyam J, Dali MM, Sahoo SK, Ma W, Chakravarthi SS, Amidon GL, et al. Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control Release. 2003;92(1–2):173–87.
Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67(3):217–23.
Fu Y, Kao WJ. Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems. Expert Opin Drug Deliv. 2010;7(4):429–44.
Alibolandi M, Sadeghi F, Sazmand SH, Shahrokhi SM, Seifi M, Hadizadeh F. Synthesis and self-assembly of biodegradable polyethylene glycol-poly (lactic acid) diblock copolymers as polymersomes for preparation of sustained release system of doxorubicin. Int J Pharm Investig. 2015;5(3):134–41.
Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond). 2011;6(4):715–28.
Xiao RZ, Zeng ZW, Zhou GL, Wang JJ, Li FZ, Wang AM. Recent advances in PEG-PLA block copolymer nanoparticles. Int J Nanomedicine. 2010;5:1057–65.
Dziadek M, Pawlik J, Menaszek E, Stodolak-Zych E, Cholewa-Kowalska K. Effect of the preparation methods on architecture, crystallinity, hydrolytic degradation, bioactivity, and biocompatibility of PCL/bioglass composite scaffolds. J Biomed Mater Res B Appl Biomater. 2015;103(8):1580–93.
Patel SP, Vaishya R, Pal D, Mitra AK. Novel pentablock copolymer-based nanoparticulate systems for sustained protein delivery. AAPS PharmSciTech. 2015;16(2):327–43.
Huang M-H, Li S, Vert M. Synthesis and degradation of PLA–PCL–PLA triblock copolymer prepared by successive polymerization of ε-caprolactone and dl-lactide. Polymer. 2004;45(26):8675–81.
Vaishya RD, Mandal A, Patel S, Mitra AK. Extended release microparticle-in-gel formulation of octreotide: effect of polymer type on acylation of peptide during in vitro release. Int J Pharm. 2015;496(2):676–88.
Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86(3):215–23.
Venkatesh P, Chawla R, Shah B, Garg SP. Surprises during intravitreal drug delivery-a report of three cases. Digit J Ophthalmol. 2017;23(1):33–5.
Thassu D, Deleers M, Pathak Y. Nanoparticulate drug delivery systems. New York: Informa Healthcare; 2007. x, 352 p., 8 p. of plates p
Tamboli V, Mishra GP, Mitra AK. Novel pentablock copolymer (PLA-PCL-PEG-PCL-PLA) based nanoparticles for controlled drug delivery: effect of copolymer compositions on the crystallinity of copolymers and in vitro drug release profile from nanoparticles. Colloid Polym Sci. 2013;291(5):1235–45.
Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm. 2005;289(1–2):1–30.
Kim HK, Park TG. Microencapsulation of human growth hormone within biodegradable polyester microspheres: protein aggregation stability and incomplete release mechanism. Biotechnol Bioeng. 1999;65(6):659–67.
Jawahar N, Meyyanathan SN. Polymeric nanoparticles for drug delivery and targeting: a comprehensive review. Int J Health Allied Sci. 2012;1:217–23. Available from: http://www.ijhas.in/text.asp?2012/1/4/217/107832.
Arifin DY, Lee LY, Wang CH. Mathematical modeling and simulation of drug release from microspheres: implications to drug delivery systems. Adv Drug Deliv Rev. 2006;58(12–13):1274–325.
Kumar R, Sinha VR. Lipid nanocarrier: an efficient approach towards ocular delivery of hydrophilic drug (Valacyclovir). AAPS PharmSciTech. 2016.
Kumar R, Nagarwal RC, Dhanawat M, Pandit JK. In-vitro and in-vivo study of indomethacin loaded gelatin nanoparticles. J Biomed Nanotechnol. 2011;7(3):325–33.
The authors would like to thank Dr. James Murowchick (Department of Geosciences, UMKC) for XRD analysis, Dr. Zhonghua Peng (Department of Chemistry, UMKC) for his assistance in GPC analysis, and Dr. Kun Cheng (Department of Pharmaceutical Sciences, UMKC) for allowing us to utilize freeze dryer.
This work was supported by National Institute of Health grants RO1 EY 09171-14, RO1 EY 10659-12, and Genentech. This work is also financially supported by Graduate Assistant Fund (GAF), UMKC Women’s Council.
Conflict of Interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Ngatuni, M.J., Trinh, H.M., Pal, D. et al. Novel Random Triblock Copolymers for Sustained Delivery of Macromolecules for the Treatment of Ocular Diseases. AAPS PharmSciTech 19, 3871–3885 (2018). https://doi.org/10.1208/s12249-018-1172-3
- random triblock copolymers
- ocular delivery
- protein and peptide
- sustained drug delivery
- controlled release